Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02743949
Other study ID # Vonoprazan-2001
Secondary ID U1111-1172-23732
Status Completed
Phase Phase 2
First received
Last updated
Start date July 14, 2016
Est. completion date October 12, 2018

Study information

Verified date February 2020
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with esomeprazole.


Description:

The drug being tested in this study is called vonoprazan. Vonoprazan is being tested to treat people who have symptomatic gastroesophageal reflux disease (GERD) with a partial response to treatment with a high dose of esomeprazole. This study will look at improvement in heartburn symptoms in participants who take vonoprazan compared to esomeprazole.

The study will enroll approximately 213 patients. All participants will receive esomeprazole or esomeprazole placebo-matching capsules (this is a capsule that looks like esomeprazole but has no active ingredient) during a 7-week run-in period. Participants will then be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

- Esomeprazole 40 mg

- Vonoprazan 20 mg

- Vonoprazan 40 mg

All participants will be asked to take one capsule at the same time each day throughout the study. All participants will be asked to record heartburn symptoms in a diary every morning upon waking and every evening before going to sleep.

This multi-center trial will be conducted in Europe. The overall time to participate in this study is 12 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 1 week after the last dose of study drug for a follow-up assessment.


Recruitment information / eligibility

Status Completed
Enrollment 256
Est. completion date October 12, 2018
Est. primary completion date October 5, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

3. Is a man or a woman and =18 years of age, at the time of the Screening visit.

4. Has a documented history of symptoms of both heartburn (burning pain) and acid regurgitation prior to entry into the study.

5. The subject has a medical history of = 8 weeks of persistent heartburn symptoms in the presence of regurgitation symptoms (persistent heartburn symptoms defined as heartburn symptoms on = 2 days a week) that are troublesome despite appropriate and correctly performed treatment with a PPI at standard doses.

6. Is =85% compliant at taking their Run-in medication and completing their e-Diary. Compliance for taking the Run-in medication is defined as the medication provided (esomeprazole and placebo) taken for 85% of the 6 weeks Run-in Period (or on 36 of 42 days of the Run-in Period).Compliance for the e-Diary is defined as the percentage of scheduled assessments that are completed based on 2 assessments per day (daytime and nighttime). For randomization, 85% compliance is required and is defined as 12 of 14 assessments completed over the 7-day period (Day -21 to Day-14) prior to the single blind Placebo Run-in Period.

7. Has a partial response to a PPI defined as having heartburn on 2 to 5 days and regurgitation on at least one day of the last week (Week 4) of a 4 week PPI Run-In Period with esomeprazole 40 mg and an increase of at least 2 symptom days of heartburn in the last week of a 2 week Placebo Run-In Period (4 to 7 symptom days) and at least one symptom day with regurgitation compared with the last week of the PPI Run-In Period.

8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 4 weeks after last dose of the study medication.

Exclusion Criteria:

1. Has received any investigational compound within 30 days prior to the Screening Visit.

2. Has received vonoprazan in a previous clinical study.

3. Is an immediate family member, study site employee, is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling), or may have consented under duress.

4. Has, in the judgment of the investigator, clinically significant abnormal hematological parameters of hemoglobin, hematocrit, or erythrocytes at Screening.

5. Has a history of erosive esophagitis of Los Angeles (LA) Classification Grade B severity or worse prior to screening or at Screening endoscopy.

6. Has a history of or any coexisting diseases affecting the esophagus (eg, Barrett's esophagus, eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, or esophageal stricture), history of radiation therapy or cryotherapy to the esophagus, caustic trauma, or physiochemical trauma such as sclerotherapy to the esophagus.

7. Has "alarm features" in symptomatology, including odynophagia, severe dysphagia, bleeding, weight loss, anemia, and blood in stool, pointing to a possible malignant disease of the gastrointestinal (GI) tract. Participants displaying "alarm symptoms" in addition to the "typical" gastroesophageal reflux disease (GERD) symptoms may be included based on endoscopic exclusion of malignancy.

8. Has current or historical chest pain due to cardiac diseases (eg, within one year).

9. Has had surgical treatment for GERD (eg, cardiaplasty), dilation of an esophageal stricture (other than Schatzki ring) or gastric or duodenal surgery, except simple oversew of an ulcer or endoscopic polypectomy of benign polyps.

10. Has active gastric or duodenal ulcers which have been confirmed by endoscopy within 30 days prior to Screening. Gastric or duodenal erosions are not exclusionary, unless considered severe and symptomatic by the investigator.

11. Has had an acute upper gastrointestinal hemorrhage within 30 days prior to Screening.

12. Has current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.

13. Has current or historical evidence of eosinophilic esophagitis (evidence may be based on the following: missing response to acid suppressive therapy, the presence of eosinophilia in histological probes of the esophageal mucosa, a normal pH profile of the distal esophagus, symptoms of dysphagia and food impaction). The exclusion of participants based on a predominance of the "typical" eosinophilic esophagitis symptoms only (as above) is considered acceptable. However, in participants with a predominance of "typical" symptoms and co-existing significant dysphagia and food impaction, the syndrome should be excluded by endoscopy with biopsy.

14. Has a documented history (within 6 months prior to screening) of functional dyspepsia (suggested by the presence of one or more of the following symptoms: epigastric pain, postprandial fullness or early satiety), or irritable bowel syndrome or other gastrointestinal diseases which are not acid-related, and therefore, are nonresponsive to gastric acid-blocking treatment.

15. Has a documented history of familial adenomatous polyposis.

16. Has known intolerance, hypersensitivity or allergies to any PPI or their components (including lansoprazole, dexlansoprazole, omeprazole, rabeprazole, pantoprazole, or esomeprazole), any component of vonoprazan, or antacid(s) selected as rescue medication for this study.

17. Has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to Screening, or regularly consumes >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week. Participants must have a negative drug screen at Screening.

18. Has evidence of a serious uncontrolled concomitant disease including: clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, systemic, or endocrine disease or other abnormality (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results.

19. Has planned, or is likely to require, in-patient surgery during the course of the study.

20. Has a history of cancer (except basal cell carcinoma of the skin) within 3 years prior to Screening.

21. Is known to have acquired immunodeficiency syndrome or chronic hepatitis due to any etiology.

22. Has abnormal laboratory values at Screening that suggest a clinically significant underlying disease or condition that may prevent the participant from completing the study.

23. Has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or T-bilirubin level which exceeds upper limit of normal (ULN) set by the testing laboratory at the Screening.

24. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.

25. Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study.

26. In the opinion of the investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vonoprazan
Vonoprazan over-encapsulated capsules
Esomeprazole
Esomeprazole over-encapsulated tablets
Esomeprazole Placebo
Esomeprazole placebo-matching capsules

Locations

Country Name City State
Belgium Medif Gozee
Belgium SPRL Dr Yvan CALOZET Grigomont
Belgium UZ Leuven Leuven
Belgium SPRL MG Balthazar & Ballard Natoye
Belgium Mortelmans, Jaak Oostham
Bulgaria DCC 'Sv. Pantaleymon' OOD Pleven
Bulgaria UMHAT "Kaspela", EOOD Plovdiv
Bulgaria MHAT - Ruse, AD Ruse
Bulgaria MHAT "Hadzhi Dimitar", OOD Sliven
Bulgaria "City Clinic UMHAC" EOOD Sofia
Bulgaria Fourth MHAT - Sofia EAD Sofia
Bulgaria MHAT 'Tokuda Hospital Sofia', EAD Sofia
Bulgaria NMTH "Tsar Boris III" Sofia
Bulgaria UMHAT "SofiaMed", OOD Sofia
Bulgaria UMHAT "Sv. Ivan Rilski", EAD Sofia
Bulgaria UMHAT 'Tsaritsa Yoanna - ISUL', EAD Sofia
Czechia Okresni nemocniceStrakonice Strakonice
Estonia Merekivi Perearstid OU Tallinn
Estonia Merelahe Family Doctors Centre Tallinn
Estonia North Estonia Medical Centre Foundation Tallinn
Estonia OU Innomedica Tallinn
Estonia West Tallinn Central Hospital Tallinn
Estonia Tartu University Hospital Tartu
Poland SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego Bialystok
Poland NZOZ Inter-Med Czestochowa
Poland Centrum Medyczne Plejady Krakow
Poland Gabinet Endoskopii Przewodu Pokarmowego Krakow
Poland Centrum Medyczne Medyk Rzeszow
Poland Specjalistyczna Praktyka Lekarska Dr med. Marek Horynski Sopot
Poland SONOMED Sp.z o.o Szczecin
Poland Niepubliczny Zaklad Opieki Zdrowotnej Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych z Torun
Poland Nzoz Vivamed Warszawa
Poland EMC Instytut Medyczny S.A. Wroclaw
Poland LexMedica Osrodek Badan Klinicznych Wroclaw
United Kingdom CPS Research Glasgow Strathclyde
United Kingdom Whipps Cross University Hospital London Greater London
United Kingdom Plympton Health Centre Plymouth Devon
United Kingdom Royal Stoke University Hospital Stoke on Trent Staffordshire
United Kingdom Sheepcot Medical Centre Watford Hertfordshire

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Countries where clinical trial is conducted

Belgium,  Bulgaria,  Czechia,  Estonia,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment Participants used the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD) every morning upon waking and every evening before going to sleep to document the presence of daytime and nighttime heartburn and regurgitation. The percentage of heartburn-free (HBF) 24-hour periods was calculated for each participant using the following formula: (total 24-hour periods that are heartburn free / total 24-hour periods for which both a daytime and nighttime result is marked) x 100%. 4 Weeks
Secondary Percentage of Participants With =1 Sustained Resolution of Heartburn During the 4-Week Treatment Period =1 sustained resolution of heartburn is defined as =7 consecutive days without both daytime and nighttime heartburn anytime during the 4-week treatment period. Daytime and nighttime heartburn were documented by all participants using the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD). 4 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05561179 - Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease N/A
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Completed NCT01946971 - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) Phase 1/Phase 2
Recruiting NCT01825473 - Study of Erythromycin in GER-Associated Apnea of the Newborn N/A
Completed NCT00614536 - Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period Phase 4
Completed NCT00373997 - Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Phase 4
Completed NCT00365300 - Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) Phase 3
Completed NCT00284908 - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers Phase 1
Completed NCT00567021 - German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms N/A
Completed NCT00215787 - Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease N/A
Completed NCT00141960 - Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease Phase 2/Phase 3
Completed NCT00226044 - Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. Phase 3
Completed NCT01167543 - Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease N/A
Completed NCT00291746 - Validation of RDQ Questionnaire Phase 4
Completed NCT01048840 - Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
Completed NCT00181805 - Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
Terminated NCT01281553 - A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease Phase 4
Completed NCT05486169 - Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy N/A
Completed NCT04034017 - Gastroesophageal Reflux Disease Among College Students
Terminated NCT03226054 - Determining Risk Factors for Successful PPI Weaning N/A